Physician profile
Amit Bhargava
NPI 1306096698
$115,607.41
in general payments reported to CMS, 2019-2025
27 companies · $6,030 in 2025
The $6,030 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $10K · 2020: $24K · 2021: $4,538 · 2022: $10K · 2023: $24K · 2024: $36K · 2025: $6,030.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $45K · Consulting Fee: $9,250 · Food and Beverage: $6,048 · Travel and Lodging: $5,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $45,405.91 |
| Consulting Fee | $9,250.00 |
| Food and Beverage | $6,048.21 |
| Travel and Lodging | $5,379.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $39,596.39 | 2021-2025 | Minimed 780g |
| Medtronic Minimed, INC. | $30,883.32 | 2019-2020 | |
| Cequr Corporation | $29,400.72 | 2022-2025 | Cequr Simplicity |
| Alexion Pharmaceuticals, INC. | $4,327.34 | 2023 | Strensiq |
| Bayer Healthcare Pharmaceuticals INC. | $3,704.59 | 2021-2024 | |
| Novo Nordisk INC | $3,377.81 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $2,022.71 | 2019-2025 | Evenity, Tepezza, Prolia |
| Dexcom, INC. | $480.23 | 2021-2024 | Dexcom G6 Transmitter, Dexcom G7 Gss (161) |
| Lilly USA, LLC | $324.41 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $272.87 | 2021-2024 | Freestyle Libre 3, Proclaim |
| Radius Health, INC. | $229.71 | 2019-2024 | Tymlos |
| Sanofi-Aventis U.S. LLC | $156.66 | 2019-2024 | |
| W. L. Gore & Associates, INC. | $138.90 | 2024 | Seamguard |
| Inspire Medical Systems, INC. | $108.93 | 2019 | |
| Insulet Corporation | $85.70 | 2022-2024 | Omnipod |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $60.25 | 2021-2024 | Gvoke Hypopen |
| Mannkind Corporation | $57.25 | 2023 | Afrezza |
| Recordati_rare_diseases_inc. | $55.34 | 2023-2025 | Isturisa, Signifor Lar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $53.46 | 2019-2023 | Jardiance, Tradjenta |
| Amneal Pharmaceuticals LLC | $51.18 | 2024 | Unithroid |
| Astrazeneca Pharmaceuticals Lp | $49.55 | 2021-2022 | |
| Antares Pharma, INC. | $41.84 | 2023-2024 | Xyosted, Nocdurna, Tlando |
| Amphastar Pharmaceuticals, INC. | $39.87 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $30.10 | 2023 | |
| Beta Bionics, INC. | $27.45 | 2023-2024 | Ilet Bionic Pancreas |
| Tandem Diabetes Care, INC. | $16.34 | 2022 | |
| Kyowa Kirin, INC. | $14.49 | 2024 | Crysvita |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amit Bhargava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.